About RareCyte
RareCyte is a Healthcare company based in Seattle (United States) founded in 2009. Developer of technologies for the analysis of rare and single cells in the blood. RareCyte has raised $114.33 million across 9 funding rounds from investors including Agilent, HHS and The Forest Road Company. RareCyte offers products and services including Orion Spatial Imager, CyteFinder II, AccuCyte Sample Prep System, RarePlex Panel Kits, and Precision Biology Services. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Kits and Reagents. Its legal entity is RARECYTE, INC. Its competitors include ArcherDX, Neogen and Parse Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
RareCyte was founded in 2009 in Seattle, United States, within the biotechnology sector. Technologies are provided for the preparation and multiparametric phenotypic analysis of rare cells from blood samples. Individual rare cell capture and retrieval for genomic analysis are supported. The platform integrates AccuCyte, a blood separation system, with CyteFinder, an instrument for cell imaging and analysis, facilitating operations in clinical and research settings.
- Headquarters Seattle, United States
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website rarecyte.com
- Social LinkedIn X YouTube
- Legal Name Rarecyte, Inc.
- Total Equity Funding$114.33M (USD)
in 9 rounds
- Latest Funding Round$20M (USD), Series C
Jun 2024
- InvestorsAgilent
& 11 more
Products & Services of RareCyte
RareCyte offers a comprehensive portfolio of products and services, including Orion Spatial Imager, CyteFinder II, AccuCyte Sample Prep System, RarePlex Panel Kits, and Precision Biology Services.
Enables high-plex spatial imaging for faster research insights.
Automates rare cell imaging and retrieval for clinical applications.
Prepares samples for liquid biopsy and molecular analysis.
Facilitates biomarker detection in spatial biology studies.
Offers custom assay development for research and trials.
Apps and channels of RareCyte
its YouTube channel RareCyte has 190 subscribers and 21 videos.
Videos from RareCyte
The most watched videos on RareCyte's YouTube channel, RareCyte (190 subscribers). Click a video to play it here.
More on RareCyte.
Funding Insights of RareCyte
RareCyte has successfully raised a total of $114.33M across 9 strategic funding rounds. The most recent funding activity was a Series C round of $20 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $114.33M
- Total Rounds 9
- Last Round Series C — $20M
- Investors Count 12
All 9 funding rounds of RareCyte with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2024 | $20M | Series C | – | F-Prime Capital, Arboretum Ventures | |
| Jul 2023 | $13.17M | Series C | – | – | – |
| Sep 2021 | $24M | Series C | – | Arboretum Ventures | |
| Dec 2019 | $22.16M | Series B | – | Health Quest Capital | |
| May 2018 | $5M | Series B | – | – | – |
| Apr 2018 | $1.99M | Grant | – | – | |
| Aug 2017 | $30M | Series B | – | 5AM Ventures | |
| Aug 2014 | $598,867 | Grant | – | – | |
| Aug 2012 | Series A | – | Telegraph Hill Partners | – |
12 investors in total: 11 institutional and 1 angel.
Investors in RareCyte
RareCyte has secured backing from 12 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Agilent, HHS and The Forest Road Company.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Healthcare venture capital investments are made by Arboretum Ventures. | arboretumvc.com | Ann Arbor, United States | ||
Investments are focused on tech and life sciences startups. | healthquestcapital.com | Belmont, United States | ||
Venture capital fund backed incubator focused on the healthcare startups | 5amventures.com | San Francisco, United States | ||
| gkcc.tcc.mode | ||||
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
Venture capital firm focused on life science, medical device and healthcare companies | thpartners.net | San Francisco, United States | ||
Diversified instruments are developed for scientific and laboratory management. | 1995 | agilent.com | Santa Clara, United States | |
Alternative investment and advisory services are provided through specialized platforms. | 2018 | forestroadco.com | New York, United States | |
| sheatreecapital.tcc.mode |
Investor details for RareCyte
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of RareCyte
31 people are tracked at RareCyte (9 in leadership, 5 in board & advisors, 17 in team).
| Name | Role | Group |
|---|---|---|
Josh Nordberg | VP, Customer Success | Leadership |
Alexandre Darmoise | Director, Sales and Applications Support, EMEA | Leadership |
Yury Colton, JD, PhD | Head Legal Counsel | Leadership |
Steve Reichenbach | CFO | Leadership |
Arturo Ramirez | VP, Biopharma Services R&D | Leadership |
Jim Cooper | VP, Finance | Leadership |
Joe Victor | President & CEO | Leadership |
Teddy Lin | Director Of Marketing | Leadership |
Alicia Allaire Langeway | Sales Director, Eastern North America | Leadership |
Robert Weisskoff | Director | Board & advisors |
Andy Schwab | Director | Board & advisors |
David Kabakoff | Director | Board & advisors |
Jan Garfinkle | Board Member, Investor | Board & advisors |
Daniel R. Marshak | Director | Board & advisors |
Brady Gardner | Senior Research Associate | Team |
Pannha Kongbouakhay | Field Applications Scientist | Team |
S. Ray Kenney | Sr Field Applications Scientist | Team |
Melinda Duplessis | Applications Scientist | Team |
Tad George | SVP, Bio R&D | Team |
Steve Reese | SVP, Engineering | Team |
11 more people are available in the full profile.
Complete people profiles for RareCyte
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of RareCyte
3 dated milestones of RareCyte across 15 years, from founding to its latest funding, stage changes and deals.
- Founded RareCyte is founded.
- Funding First funding round.
- Funding Latest funding round, Series C, of $20.0M.
Competitors of RareCyte
RareCyte has 3 listed competitors in our database, 3 of them funded. They include ArcherDX, Neogen and Parse Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| neogen.com | 1982 | Lansing, United States | $700,000 | 2,640 | Manufacturer of products in the areas of veterinary diagnostics, life sciences, DNA testing, and drug testing | |
| parsebiosciences.com | 2018 | Seattle, United States | $100.26M | RNA-sequencing transcriptome kits for health data analysis are developed. |
Detailed competitors of RareCyte
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of RareCyte
The website of RareCyte (rarecyte.com) receives about 3.2K visits a month and ranks #5,681,690 among all websites worldwide, #6,198 in Biotechnology and Pharmaceuticals.
- Monthly visits3.2K
▲ 11% vs previous month
- Unique visitors1.2K
per month
- Global rank#5,681,690
among all websites
- Category rank#6,198
Health · Biotechnology and Pharmaceuticals
- Bounce rate36%
- Pages per visit1.8
- Average visit31 sec
- DevicesDesktop 39% · Mobile 61%
Websites whose visitors overlap most with RareCyte. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| shapetx.com | 100% | 2K | #11,569,347 | View details | |
| omeros.com | 100% | 15.6K | #1,695,799 | View details | |
| dendreon.com | 97% | 17.6K | #885,568 | View details | |
| adaptivebiotech.com | 85% | 63.9K | #807,876 | View details | |
| zymeworks.com | 85% | 32.9K | #989,344 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 24 similar websites and full traffic analytics for RareCyte
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 24 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as RareCyte (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rarecyte
Complete news archive for RareCyte
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about RareCyte
RareCyte was founded in 2009 and raised its 1st funding round 3 years after it was founded.
RareCyte is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
RareCyte is a funded company, having raised a total of $114.33M across 9 funding rounds to date.
RareCyte was founded in 2009 in Seattle, United States, within the biotechnology sector. Technologies are provided for the preparation and multiparametric phenotypic analysis of rare cells from blood samples. Individual rare cell capture and retrieval for genomic analysis are supported. The platform integrates AccuCyte, a blood separation system, with CyteFinder, an instrument for cell imaging and analysis, facilitating operations in clinical and research settings.
RareCyte's top competitors include Neogen, Parse Biosciences and ArcherDX.
RareCyte offers Orion Spatial Imager, CyteFinder II, AccuCyte Sample Prep System, RarePlex Panel Kits, and Precision Biology Services.
RareCyte has 12 investors. Key investors include Agilent, HHS, The Forest Road Company, F-Prime Capital, and Arboretum Ventures.
RareCyte operates through Rarecyte, Inc..